Liver toxicity associated with these therapies reflects a multifaceted pathogenesis. Targeted drugs, mainly tyrosine kinase inhibitors (TKIs) such as lenvatinib and sorafenib, undergo hepatic metabolism primarily via the cytochrome P450 enzyme system. Their biotransformation can generate reactive intermediates leading to oxidative stress, mitochondrial dysfunction, and the activation of apoptotic cascades within hepatocytes. This intrinsic or idiosyncratic injury may further be exacerbated by immune-mediated mechanisms. Meanwhile, ICIs, by blocking immune checkpoints like PD-1 and CTLA-4, unleash cytotoxic T-cell responses. This immune activation, while beneficial in antitumor effects, can cause unchecked T cell-mediated hepatocyte damage, manifesting as immune-related liver injury (ILICI), characterized histologically by intense lobular infiltration of CD8+ T cells and immune-mediated cholangitis.

Epidemiological data indicate substantial variability in the incidence of liver injury across different therapeutic agents and regimens. For instance, TKIs demonstrate alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation in approximately 9–25% of treated patients. Higher hepatotoxicity rates have been seen with vascular endothelial growth factor receptor (VEGFR) antagonists like apatinib. ICIs, including PD-1 inhibitors, show liver enzyme elevations in about 9–26% of cases, with combination therapies such as nivolumab plus ipilimumab or camrelizumab combined with apatinib frequently pushing these rates beyond 50%. When systemic regimens are coupled with locoregional interventions like transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC), the risk and severity of liver injury increase substantially, underscoring the critical need for vigilant monitoring.

Identifying patients at heightened risk is essential for preemptive management. Underlying chronic liver diseases, particularly chronic hepatitis B or C infections, drastically increase vulnerability to liver injury during systemic therapy. The compromised hepatic reserve in patients categorized as Child-Pugh B is another potent risk factor. Genetic polymorphisms in drug-metabolizing enzymes significantly influence drug clearance and toxicity. For example, variations in UGT1A1 and UGT1A9 genes have been correlated with sorafenib and regorafenib-associated hyperbilirubinemia, respectively. Furthermore, patient demographics such as younger age and the concurrent use of hepatotoxic medications, including acetaminophen, add layers of complexity to individualized risk profiles.

Given the high stakes, rigorous pre-treatment assessment protocols are advocated. Baseline evaluations must confirm that patients demonstrate adequate hepatic functional reserve, with Child-Pugh scores not exceeding 7, and liver enzymes (ALT, AST) and total bilirubin (TBIL) levels within defined safety margins (ALT/AST ≤ 3 times upper limit of normal (ULN), TBIL ≤ 1.5 times ULN). Comprehensive viral screening for hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), and anti-hepatitis C virus (anti-HCV) is mandated. Patients positive for HBsAg require antiviral therapy initiation at least one week prior to systemic treatment onset. Similarly, those with detectable HCV RNA are to receive direct-acting antiviral regimens, mitigating the risk of viral reactivation and liver decompensation during therapy.

The clinical spectrum of liver injury induced by these agents ranges from asymptomatic elevations of liver enzymes to severe hepatitis presenting with nonspecific symptoms such as fatigue, nausea, and jaundice. Histopathological examination often reveals distinct patterns corresponding to drug class. Targeted therapy-induced injuries may manifest as mixed hepatocellular and cholestatic damage with evidence of mitochondrial and oxidative injury, while ICI-related liver injuries predominantly show immune-mediated hepatitis marked by dense CD8+ T-cell infiltrates or immune-mediated cholangitis involving bile duct epithelial injury.

Accurate diagnosis hinges on correlating liver test abnormalities temporally with drug exposure and resolution upon drug withdrawal. Importantly, the diagnostic process requires exclusion of differential causes such as viral hepatitis flare-ups, tumor progression, other hepatotoxic medications, autoimmune hepatitis, and rare but critical conditions like myocarditis or myositis when AST is disproportionately elevated relative to ALT. Liver biopsy plays an indispensable role in ambiguous cases or those with severe, refractory liver injury, providing histologic clarity that guides therapeutic decisions.

The consensus presents a refined grading system for liver injury severity, integrating clinical symptoms, biochemical parameters including ALT, AST, alkaline phosphatase (ALP), TBIL, and coagulation metrics such as prothrombin activity (PTA) or international normalized ratio (INR). This evidence-based stratification undergirds tailored management strategies that balance hepatoprotective therapy with judicious modification or cessation of offending agents.

For injuries induced by targeted therapies, mild cases (Grade 1) permit continued treatment supplemented with liver-protective agents such as magnesium isoglycyrrhizinate and bicyclol. Moderate injuries (Grade 2) prompt considerations for dose reduction alongside amplified hepatoprotection. Severe cases (Grade 3) necessitate temporary discontinuation, with cautious reintroduction at a lower dose after recovery. The most critical injuries (Grade 4) demand permanent discontinuation and aggressive supportive care, potentially including artificial liver support technologies to manage hepatic failure.

In the realm of ICI-induced liver injury, mild elevations (Grade 1) do not preclude ongoing immune therapy but require close monitoring. Grade 2 injuries call for temporary cessation of ICIs and initiation of hepatoprotective agents. More severe presentations (Grade 3) obligate permanent discontinuation and commencement of glucocorticoids at doses ranging from 0.5 to 1.0 mg/kg/day. Life-threatening (Grade 4) instances mandate permanent discontinuation and administration of high-dose corticosteroids (1–2 mg/kg/day), with second-line immunosuppressants such as mycophenolate mofetil or tacrolimus reserved for steroid-refractory scenarios.

In cases of combination treatments, pinpointing the dominant agent responsible for hepatotoxicity is crucial. Subsequent rechallenge strategies may consider alternative agents with careful risk-benefit evaluations based on prior toxicity profiles and clinical judgment.

Post-therapy, patients require diligent follow-up involving serial liver function tests and imaging every 4 to 6 weeks to monitor for recurrent liver injury and assess tumor progression. The prognosis for mild to moderate liver injuries is favorable with timely intervention. Most patients experiencing moderate to severe ICI-related liver injury respond well to corticosteroid therapy; however, a subset may exhibit prolonged recovery trajectories demanding sustained immunosuppressive management.

Despite these advances, significant knowledge gaps persist. The precise molecular pathways mediating liver injury from both targeted therapies and ICIs warrant further elucidation, which may unveil predictive biomarkers for susceptibility. The effectiveness and timing of prophylactic hepatoprotective strategies remain to be definitively established. Moreover, optimal management paradigms for complex combination regimens involving systemic and locoregional therapies require continued refinement. The consensus represents a dynamic, living document that will be iteratively updated as accumulating evidence reshapes our understanding and capabilities to mitigate liver injury while maximizing oncologic outcomes.

This groundbreaking consensus stands as a pivotal resource, providing oncologists, hepatologists, and multidisciplinary care teams with an authoritative, evidence-driven framework to navigate the multifarious challenges posed by drug-induced liver injury in the era of advanced HCC therapeutics. The guideline’s meticulous integration of mechanistic insights, clinical stratification, and pragmatic management principles underscores a paradigm shift toward personalized, proactive care, ultimately safeguarding patient safety without compromising anti-cancer efficacy.

Subject of Research: Management of liver injury associated with targeted drugs and immune checkpoint inhibitors in hepatocellular carcinoma.

Article Title: Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024)

News Publication Date: 12-Sep-2025

Web References:
– Journal of Clinical and Translational Hepatology, https://www.xiahepublishing.com/journal/jcth
– DOI: http://dx.doi.org/10.14218/JCTH.2025.00228

Image Credits: Yuemin Nan, Xiaoyuan Xu, Jingfeng Liu

Keywords: Hepatocellular carcinoma, Liver injury, Drug-induced liver injury, Tyrosine kinase inhibitors, Immune checkpoint inhibitors, Targeted therapy, Immune-mediated liver injury, Hepatotoxicity, Drug metabolism, Cytochrome P450, Immune-related adverse events

Hepatic ischemia–reperfusion injury arises when the blood supply to the liver is transiently interrupted and then restored, a process common during liver transplantation, resection surgeries, or shock scenarios. The sudden reoxygenation event paradoxically leads to an overwhelming burst of reactive oxygen species (ROS) production, triggering cellular damage, inflammation, and often severe organ dysfunction. Despite decades of research, effective pharmacological solutions to mitigate this reperfusion injury have eluded clinicians, underscoring the importance of novel approaches such as the one recently reported.

Central to this breakthrough is the use of biosilica-based nanoparticles. These nanostructures are derivatized silica forms synthesized through biomimetic mineralization processes, leveraging the biological production pathways found in diatoms and sponges. Their porous architecture and inherent biocompatibility make them ideal carriers and active agents for scavenging highly reactive radicals causing oxidative damage. The researchers designed these biosilica nanoparticles to act as ROS “sponges,” efficiently neutralizing harmful species before they can incite cellular injury.

The engineered nanoparticles exhibit several distinct advantages that underscore their therapeutic potential. Biosilica’s robust surface chemistry can be modified to enhance targeting and circulation time, while its biodegradability ensures minimal long-term toxicity. In preclinical models, these particles demonstrated remarkable efficacy in localizing to hepatic tissue undergoing reperfusion stress, where their scavenging activity drastically lowered oxidative markers and inflammatory cytokines. Such result-oriented design marks a significant leap beyond inert antioxidant therapies, which often lack tissue-specific accumulation.

Mechanistic studies revealed that these biosilica nanoparticulate scavengers interrupt the ROS-mediated signaling pathways that drive cell death and inflammation during reperfusion. By depleting excess hydroxyl radicals and superoxide anions, the nanoparticles prevent mitochondrial dysfunction—a critical early event in hepatic injury. Moreover, the particles appear to modulate immune cell activation, curtailing the recruitment and overactivation of neutrophils and macrophages that exacerbate tissue damage. This dual action both protects hepatocytes and tempers the injurious inflammatory milieu.

In vivo experiments in rodent models of liver ischemia–reperfusion injury yielded compelling data. Animals treated with biosilica nanoparticles prior to reperfusion showed dramatically improved liver function tests, reduced histological evidence of necrosis, and better overall survival compared to controls. Importantly, no adverse effects were detected, highlighting the safety profile of biosilica as a therapeutic scaffold. These findings substantially elevate the clinical translation prospects for nanoparticle-based therapies in hepatic injury management.

The implications of this research extend well beyond liver IRI. Biosilica nanoparticulate scavengers open up new horizons for treating a variety of oxidative stress-related pathologies where localized and sustained ROS neutralization is desirable. This includes myocardial infarction, stroke, and even certain neurodegenerative diseases where aberrant ROS production plays a critical role. The modularity of biosilica nanoparticle design enables adaptation for diverse clinical contexts, potentially transforming multiple fields of medicine.

One of the most exciting aspects of these nanoparticles is their biomimetic origin which aligns with sustainable and biologically harmonious therapeutic approaches. Unlike synthetic nanoparticles laden with heavy metals or complex organic compounds, biosilica offers a safer, environmentally benign alternative with straightforward scalability. This compatibility could accelerate regulatory approval and expedite the integration of these nanoparticles into clinical routines, creating a seamless interface between nature-inspired materials science and practical medicine.

The pathway from bench to bedside for biosilica nanoparticulate scavengers involves several essential steps. Scaling up production with consistent quality, optimizing dosing regimens, and conducting rigorous trials in larger animal models are next on the horizon. Additionally, further refinement of particle functionalization to enhance selective delivery, minimize off-target effects, and enable real-time monitoring of therapeutic activity will maximize clinical efficacy. Ongoing multidisciplinary collaborations are vital to navigate these challenges effectively.

From a broader scientific perspective, this study catalyzes a paradigm shift in nanomedicine by emphasizing bioinspired materials for active therapeutic functions rather than mere drug delivery vehicles. The ability of biosilica nanoparticles to directly interact with and neutralize pathological mediators such as ROS paves the way for a new class of “nanoscavengers” that can intervene in complex biochemical networks in situ. This conceptual breakthrough opens diverse opportunities for future innovation in precision medicine and pathology interception.

Furthermore, the success demonstrated in hepatic IRI models highlights the importance of addressing oxidative stress as a central target in acute organ injuries. By effectively quenching ROS bursts, tissue homeostasis can be restored prior to irreversible damage. This approach could substantially reduce morbidity associated with ischemic disorders, decrease reliance on invasive procedures, and improve patient prognoses globally. As such, it aligns with broader healthcare goals aimed at enhancing therapeutic efficacy while minimizing adverse outcomes.

The study also underscores the critical role of interdisciplinary integration, combining expertise in materials science, biomedical engineering, molecular biology, and clinical medicine. The innovations in nanoparticle synthesis and functionalization drew heavily on advanced characterization tools such as electron microscopy, spectroscopy, and in vivo imaging, enabling precise structural and functional tailoring. Such cooperative strategies exemplify modern translational research’s power to deliver transformative therapies advancing human health.

Looking ahead, the broader adoption of biosilica-based therapeutics requires strategic partnerships spanning academia, industry, and regulatory bodies. Efforts to standardize nanoparticle characterization, manufacturing processes, and safety assessment protocols will be essential to facilitate commercialization. Moreover, educating clinicians about the principles and advantages of biosilica nanomedicine will foster acceptance and appropriate application in clinical settings, ensuring these innovations translate into tangible patient benefits.

The therapeutic promise also invites ethical and socioeconomic considerations, emphasizing equitable access to advanced nanomedicine treatments. Incorporating cost-effectiveness analyses and health policy initiatives early in development can guide responsible dissemination and address disparities in healthcare delivery. Such foresight ensures that cutting-edge nanoscale therapies do not become confined to privileged populations but serve broad patient communities worldwide.

In conclusion, the advent of biosilica nanoparticulate scavengers marks a transformative milestone in the fight against hepatic ischemia–reperfusion injury. By harnessing nature’s blueprint and nanoscale engineering precision, this strategy offers robust, targeted, and safe protection against the devastating cascade of oxidative damage in liver tissues. As research propels this technology closer to clinical reality, it heralds a new era of biomaterial-enabled therapeutics poised to redefine organ injury treatment and improve millions of lives.

Subject of Research: Hepatic ischemia–reperfusion injury therapy using biosilica nanoparticles.

Article Title: Biosilica nanoparticulate scavengers for the therapy of hepatic ischemia–reperfusion injury in preclinical models.

Article References:
Zhou, B., Chen, X., Ding, R. et al. Biosilica nanoparticulate scavengers for the therapy of hepatic ischemia–reperfusion injury in preclinical models. Nat Commun 16, 7650 (2025). https://doi.org/10.1038/s41467-025-62968-4

Image Credits: AI Generated